Medlab Clinical (ASX:MDC) - Share price, News & Analysis

MDC fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

MDC Stock Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia.

Rewards

Revenue is forecast to grow 26.11% per year

Risk Analysis

Earnings are forecast to decline by an average of 18.6% per year for the next 3 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (A$4M)

+ 1 more risk

Medlab Clinical Competitors

Exopharm

ASX:EX1

AU$24.4m

Alterity Therapeutics

ASX:ATH

AU$38.5m

BCAL Diagnostics

ASX:BDX

AU$20.7m

Immuron

ASX:IMC

AU$23.3m

Price History & Performance

Summary of all time highs, changes and price drops for Medlab Clinical
Historical stock prices
Current Share Price	AU$0.078
52 Week High	AU$0.20
52 Week Low	AU$0.077
Beta	1.11
1 Month Change	-25.71%
3 Month Change	-35.00%
1 Year Change	-55.43%
3 Year Change	-80.25%
5 Year Change	-90.13%
Change since IPO	-61.00%

Recent News & Updates

Oct 06

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Shareholders of Medlab Clinical Limited ( ASX:MDC ) will have been dismayed by the negative share price return over the...

Oct 05

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	MDC	AU Biotechs	AU Market
7D	0%	0.5%	-1.2%
1Y	-55.4%	-8.0%	-0.009%

Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -9% over the past year.

Return vs Market: MDC underperformed the Australian Market which returned 0.5% over the past year.

Price Volatility

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement	10.6%
Biotechs Industry Average Movement	9.9%
Market Average Movement	9.3%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	4.2%

Stable Share Price: MDC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MDC's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Sean Hall	https://www.medlab.co

Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oro–buccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiring–bone–pain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients.

Medlab Clinical Fundamentals Summary

How do Medlab Clinical's earnings and revenue compare to its market cap?
MDC fundamental statistics
Market Cap	AU$26.69m
Earnings (TTM)	-AU$11.99m
Revenue (TTM)	AU$4.47m

6.0x

P/S Ratio

-2.2x

P/E Ratio

Is MDC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDC income statement (TTM)
Revenue	AU$4.47m
Cost of Revenue	AU$2.78m
Gross Profit	AU$1.69m
Other Expenses	AU$13.68m
Earnings	-AU$11.99m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.035
Gross Margin	37.82%
Net Profit Margin	-268.08%
Debt/Equity Ratio	0%

How did MDC perform over the long term?

See historical performance and comparison

New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-18.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDC's revenue (26.1% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: MDC's revenue (26.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Medlab Clinical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-27.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDC is currently unprofitable.

Growing Profit Margin: MDC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.

Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).

Return on Equity

High ROE: MDC has a negative Return on Equity (-101.43%), as it is currently unprofitable.

Financial Health

How is Medlab Clinical's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDC's short term assets (A$13.7M) exceed its short term liabilities (A$3.3M).

Long Term Liabilities: MDC's short term assets (A$13.7M) exceed its long term liabilities (A$965.6K).

Debt to Equity History and Analysis

Debt Level: MDC is debt free.

Reducing Debt: MDC has no debt compared to 5 years ago when its debt to equity ratio was 6.6%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.8% each year

Dividend

What is Medlab Clinical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDC has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average board tenure

CEO

Sean Hall

no data

Tenure

AU$676,770

Compensation

Dr. Sean Michael Hall serves as the Chief Executive Officer at Medlab Clinical Limited and served as its Managing Director. He served as a Managing Director of Medlab Clinical Limited until November 2020....

CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD481.07K) is above average for companies of similar size in the Australian market ($USD287.06K).

Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.

Board Members

Experienced Board: MDC's board of directors are considered experienced (7.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: MDC insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30